Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Prostatic Neoplasms Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

3 recruiting trials for Prostatic Neoplasms. Eligibility criteria explained in plain English.

TrialFinderData lists 3 Prostatic Neoplasms clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Every phased trial in this set is Phase 2 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.

Research is led by Assiut University (1), National Cancer Institute (NCI) (1), Janssen Cilag S.A.S. (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is PSMA PET/CT (device, 1 trial), followed by 18F-DCFPyL, Stereotactic Body Radiation Therapy.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
3
Total Trials
3
Recruiting Now
0
Phase 3 Trials
3
Sponsors

Track Prostatic Neoplasms trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT06209853

Correlation Between PSA Levels and F-18 PSMA PET/CT Findings in Prostate Cancer Patient

It is a cross sectional study aimed to correlate between PSA Levels and F-18 PSMA PET/CT Scan findings and to evaluate the impact of PET/CT findings on the patient management

Sponsor: Assiut UniversityEnrolling: 591 location
RECRUITINGPhase 2NCT05616650

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

Background: The current standard treatment of prostate cancer is either surgery or radiation. Typically, this includes either the removal or radiation of the whole prostate...

Sponsor: National Cancer Institute (NCI)Enrolling: 421 location
RECRUITINGNCT07451002

A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France

This study aims to explore the real-world treatment adherence, persistence of apalutamide, and assess the risk of non-adherence according to the participant's profile and behavior...

Sponsor: Janssen Cilag S.A.S.Enrolling: 2701 location

Frequently Asked Questions

There are currently 3 clinical trials for Prostatic Neoplasms, with 3 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Prostatic Neoplasms, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Prostatic Neoplasms, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.